Two insulin biosimilars, Sanofi’s Truvelog Mix 30 rival to NovoMix (insulin aspart) and Baxter’s Inpremzia version of Actrapid (insulin human rDNA) have been granted positive opinions recommending pan-European marketing authorizations by the committee for medicinal products for human use within the European Medicines Agency.
Truvelog Mix 30 will be available as a 100U/ml suspension for injection while Inpremzia will be available as 1IU/ml solution...






